Premium
Identification and distribution of thioredoxin‐like 2 as the antigen for the monoclonal antibody MC3 specific to colorectal cancer
Author(s) -
Lu Yuanyuan,
Wang Xin,
Liu Zhenxiong,
Jin Bin,
Chu Dake,
Zhai Huihong,
Zhang Faming,
Li Kai,
Ren Gui,
MirandaVizuete Antonio,
Guo Xuegang,
Fan Daiming
Publication year - 2008
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200700770
Subject(s) - monoclonal antibody , colorectal cancer , antigen , biology , identification (biology) , computational biology , thioredoxin , cancer , antibody , immunology , genetics , gene , ecology
MC3 is a colorectal cancer (CRC)‐specific mAb previously prepared in our laboratory that can detect CRC with high sensitivity and specificity. However, the target antigen for MC3 had not been identified due to technological limitations. In the present study, immunocytochemistry and immunohistochemistry revealed the expression patterns of MC3 antigen (MC3‐Ag) in colon cancer cell lines and CRC tissues. Western blotting analysis showed that the MC3 antibody reproducibly recognized two ∼30 kDa proteins in the total cell lysates of human colon carcinoma cell lines SW480 and HT‐29. Using a proteomic approach, we identified two MC3 immunoreactive spots as two isoforms of thioredoxin‐like 2 (Txl‐2) protein. Further paired immunostaining showed that Txl‐2 had the same expression profile as probed by the MC3 antibody. Western blotting also showed that both antibodies could detect the same two bands, further verifying that Txl‐2 is the antigen of MC3 antibody. Additionally, tissue arrays revealed the expression patterns of Txl‐2 in various normal and cancer tissues. Further analysis showed that Txl‐2 mRNA was elevated in 18 cases of CRC tissues compared to paracancerous tissues and adjacent normal tissues.